A practical algorithm for managing Alzheimer's disease: what, when, and why?

Annals of Clinical and Translational Neurology

Volumn 2, Issue 3, 2015, Pages 307-323

  Cummings, Jeffrey L ^a   Isaacson, Richard S ^b   Schmitt, Frederick A ^c   Velting, Drew M ^d  

^a Las Vegas   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; RIVASTIGMINE;

ALGORITHM; ALZHEIMER DISEASE; APATHY; CARDIOVASCULAR RISK FACTOR; CAREGIVER; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIETARY PATTERN; DRUG THERAPY; DSM-5; DSM-IV; EATING DISORDER; HEALTH CARE; HUMAN; IRRITABILITY; LEGAL ASPECT; LIFESTYLE; MINI MENTAL STATE EXAMINATION; MOOD DISORDER; PHYSICAL ACTIVITY; PREVALENCE; PSYCHOSIS; QUALITY OF LIFE; RESIDENTIAL CARE; REVIEW; SLEEP DISORDER; SLEEP QUALITY; UNIFIED PARKINSON DISEASE RATING SCALE; WELLBEING;

EID: 84930697738     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.166     Document Type: Review

References (132)

1. Alzheimer's Association. 2014 Alzheimer's disease facts and figures. Alzheimers Dement 2014;10:e47–e92.
2. Wimo A, Prince M. World Alzheimer Report 2010: the global economic impact of dementia. London, UK: Alzheimer's Disease International, 2010.
3. Cummings JL, Cole G. Alzheimer disease. JAMA 2002;287:2335–2338.
4. Lopez OL. The growing burden of Alzheimer's disease. Am J Manag Care 2011;17(suppl 13):S339–S345.
5. Alzheimer's Disease International. World Alzheimer Report, 2009. Available at http://www.alz.co.uk/research/files/WorldAlzheimerReport.pdf (accessed 21 November 2014).
6. Kaufer DI, Cummings JL, Christine D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998;46:210–215.
7. California Workshop on Guidelines for Alzheimer's Disease Management. Guidelines for Alzheimer's disease management. Final report 2008.
8. Iliffe S, Wilcock J, Haworth D. Obstacles to shared care for patients with dementia: a qualitative study. Fam Pract 2006;23:353–362.
9. Alzheimer's Disease International. World Alzheimer Report 2014. Available at http://www.alz.co.uk/research/world-report-2014 (accessed 21 November 2014).
10. Otaegui-Arrazola A, Amiano P, Elbusto A, et al. Diet, cognition, and Alzheimer's disease: food for thought. Eur J Nutr 2014;53:1–23.
11. Reiner M, Niermann C, Jekauc D, Woll A. Long-term health benefits of physical activity–a systematic review of longitudinal studies. BMC Public Health 2013;13:813.
12. Williams JW, Plassman BL, Burke J, et al. Preventing Alzheimer's disease and cognitive decline. Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, 2010. Contract No.: 10-E005.
13. Nelson PT, Smith CD, Abner EA, et al. Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta 2009;1792:454–469.
14. Wysocki M, Luo X, Schmeidler J, et al. Hypertension is associated with cognitive decline in elderly people at high risk for dementia. Am J Geriatr Psychiatry 2012;20:179–187.
15. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 2010;304:1903–1911.
16. Shinto L, Quinn J, Montine T, et al. A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease. J Alzheimers Dis 2014;38:111–120.
17. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006;63:1402–1408.
18. Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci USA 2013;110:9523–9528.
19. Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int J Geriatr Psychiatry 2008;23:155–160.
20. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014;311:33–44.
21. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216–1222.
22. Chua ME, Sio MC, Sorongon MC, Morales ML, Jr. The relevance of serum levels of long chain omega-3 polyunsaturated fatty acids and prostate cancer risk: a meta-analysis. Can Urol Assoc J 2013;7:E333–E343.
23. Cadell LS, Clare L. I'm still the same person: the impact of early-stage dementia on identity. Dementia 2011;10:379–398.
24. Judge KS, Menne HL, Whitlatch CJ. Stress process model for individuals with dementia. Gerontologist 2010;50:294–302.
25. Phinney A, Dahlke S, Purves B. Shifting patterns of everyday activity in early dementia: experiences of men and their families. J Fam Nurs 2013;19:348–374.
26. Van Dijkhuizen M, Clare L, Pearce A. Striving for connection: appraisal and coping among women with early-stage Alzheimer's disease. Dementia 2006;5:73–94.
27. Clare L, Goater T, Woods B. Illness representations in early-stage dementia: a preliminary investigation. Int J Geriatr Psychiatry 2006;21:761–767.
28. Roberts JS, Silverio E. Evaluation of an education and support program for early-stage Alzheimer's disease. J Appl Gerontol 2009;28:419–435.
29. Beard R. Art therapies and dementia care: a systematic review. Dementia 2012;11:633–656.
30. Koger SM, Chapin K, Brotons M. Is music therapy an effective intervention for dementia? A meta-analytic review of literature. J Music Ther 1999;36:2–15.
31. Gotell E, Brown S, Ekman SL. The influence of caregiver singing and background music on vocally expressed emotions and moods in dementia care: a qualitative analysis. Int J Nurs Stud 2009;46:422–430.
32. Brotons M, Koger SM. The impact of music therapy on language functioning in dementia. J Music Ther 2000;37:183–195.
33. Guetin S, Portet F, Picot MC, et al. Effect of music therapy on anxiety and depression in patients with Alzheimer's type dementia: randomised, controlled study. Dement Geriatr Cogn Disord 2009;28:36–46.
34. Filan SL, Llewellyn-Jones RH. Animal-assisted therapy for dementia: a review of the literature. Int Psychogeriatr 2006;18:597–611.
35. Holt FE, Birks TPH, Thorgrimsen LM, et al. Aroma therapy for dementia. Cochrane Database Syst Rev 2003;3:CD003150.
36. Öhman A, Nygård L. Meaning and motives for engagement in self-chosen daily life occupations among individuals with Alzheimer's disease. OTJR 2005;25:89–97.
37. Sitzer DI, Twamley EW, Jeste DV. Cognitive training in Alzheimer's disease: a meta-analysis of the literature. Acta Psychiatr Scand 2006;114:75–90.
38. Femia EE, Zarit SH, Stephens MA, Greene R. Impact of adult day services on behavioral and psychological symptoms of dementia. Gerontologist 2007;47:775–788.
39. De Vreese LP, Neri M, Fioravanti M, et al. Memory rehabilitation in Alzheimer's disease: a review of progress. Int J Geriatr Psychiatry 2001;16:794–809.
40. APA. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994.
41. APA. Highlights of changes from DSM-IV-TR to DSM-5. Arlington, Virginia: American Psychiatric Association, 2013.
42. Jack CR, Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:257–262.
43. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280–292.
44. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270–279.
45. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263–269.
46. Galvin JE, Sadowsky CH. Practical guidelines for the recognition and diagnosis of dementia. J Am Board Fam Med 2012;25:367–382.
47. Sadowsky CH, Galvin JE. Guidelines for the management of cognitive and behavioral problems in dementia. J Am Board Fam Med 2012;25:350–366.
48. Lindstrom HA, Smyth KA, Sami SA, et al. Medication use to treat memory loss in dementia: perspectives of persons with dementia and their caregivers. Dementia 2006;5:27–50.
49. ®) US Prescribing Information. 2010. Available at http://www.aricept.com/docs/pdf/aricept_PI.pdf (accessed 21 November 2014).
50. ®) Prescribing Information. 2005. Available at: http://www.razadyneer.com/sites/default/files/shared/pi/razadyne_er.pdf#zoom=100 (accessed 21 November 2014).
51. ®) US Prescribing Information. 2006. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020823s016,021025s008lbl.pdf (accessed 21 November 2014).
52. ®). US Prescribing Information. 2009. Revised 2012 and 2013. Available at http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf (accessed 21 November 2014).
53. Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32:1234–1251.
54. 2 in Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:341–353.
55. Farlow MR, Grossberg GT, Sadowsky CH, et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther 2013;19:745–752.
56. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;1:CD005593.
57. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379–397.
58. Geldmacher DS. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry 2007;9:113–121.
59. Rabins PV, Blacker D, Rovner BW, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 2007;164:5–56.
60. Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000;2:68–72.
61. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719–739.
62. Oertel W, Ross JS, Eggert K, Adler G. Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007;69:S4–S9.
63. Hing JP, Piotrovsky V, Kimko H, et al. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Curr Med Res Opin 2005;21:483–488.
64. Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:120–132.
65. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456–467.
66. ®) tablets/oral solution. US Prescribing Information. 2013. Available at http://pi.actavis.com/data_stream.asp?product_group=1901&p=pi&language=E (accessed 21 November 2014).
67. ®) XR US Prescribing Information. 2010. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022525s000lbl.pdf (accessed 21 November 2014).
68. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333–1341.
69. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317–324.
70. Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 2013;27:469–478.
71. Qaseem A, Snow V, Cross JT, Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148:370–378.
72. Caprylidene US Prescribing Information. 2012. Available at http://www.about-axona.com/assets/files/us-en/global/pdf/Axona-PrescribingInformation.pdf (accessed 21 November 2014).
73. ® Caplets US Prescribing Information. 2012. Available at http://www.drugs.com/cdi/cerefolin-with-nac.html (accessed 21 November 2014).
74. ® US Prescribing Information. 2012. Available at http://vayacog.com/wp-content/uploads/2012/09/Vayacog-Sample-Outsert-Rev.-8-copy.pdf (accessed 21 November 2014).
75. Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31.
76. Galvin JE. Optimizing diagnosis and management in mild-to-moderate Alzheimer's disease. Neurodegener Dis Manag 2012;2:291–304.
77. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007;369:208–216.
78. Vakhapova V, Cohen T, Richter Y, et al. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord 2010;29:467–474.
79. Scheltens P, Kamphuis PJ, Verhey FR, et al. Efficacy of a medical food in mild Alzheimer's disease: a randomized, controlled trial. Alzheimers Dement 2010;6:1–10.e11.
80. Scheltens P, Twisk JW, Blesa R, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimers Dis 2012;31:225–236.
81. Kamphuis PJ, Verhey FR, Olde Rikkert MG, et al. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672–676.
82. Lyle S, Grizzell M, Willmott S, et al. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. Dement Geriatr Cogn Disord 2008;25:226–231.
83. Doraiswamy PM, Leon J, Cummings JL, et al. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2002;57:M173–M177.
84. Zhao Y, Kuo TC, Weir S, et al. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer's. BMC Health Serv Res 2008;8:108.
85. Duthie A, Chew D, Soiza RL. Non-psychiatric comorbidity associated with Alzheimer's disease. QJM 2011;104:913–920.
86. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1–e26.
87. Lavie P, Herer P, Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. BMJ 2000;320:479–482.
88. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034–2041.
89. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011;306:613–619.
90. Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. Alzheimers Dement 2013;9:602–608.
91. Fernandez M, Gobartt AL, Balana M. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. BMC Neurol 2010;10:87.
92. Garcia-Alberca JM, Pablo Lara J, Gonzalez-Baron S, et al. [Prevalence and comorbidity of neuropsychiatric symptoms in Alzheimer's disease]. Actas Esp Psiquiatr 2008;36:265–270.
93. Youn JC, Lee DY, Jhoo JH, et al. Prevalence of neuropsychiatric syndromes in Alzheimer's disease (AD). Arch Gerontol Geriatr 2011;52:258–263.
94. Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry 2012;169:900–906.
95. Cumbo E, Ligori LD. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial. J Alzheimers Dis 2014;39:477–485.
96. Bains J, Birks JS, Dening TR. The efficacy of antidepressants in the treatment of depression in dementia. Cochrane Database Syst Rev 2002;4:CD003944.
97. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. J Am Geriatr Soc 2011;59:577–585.
98. Majic T, Pluta JP, Mell T, et al. The pharmacotherapy of neuropsychiatric symptoms of dementia: a cross-sectional study in 18 homes for the elderly in Berlin. Dtsch Arztebl Int 2010;107:320–327.
99. Rayner AV, O'Brien JG, Schoenbachler B. Behavior disorders of dementia: recognition and treatment. Am Fam Physician 2006;73:647–652.
100. Tariot PN, Schneider LS, Mintzer JE, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res 2001;61:51–67.
101. Fleisher AS, Truran D, Mai JT, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology 2011;77:1263–1271.
102. Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68:853–861.
103. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007;23:2705–2713.
104. Beusterien KM, Thomas SK, Gause D, et al. Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs 2004;18:1143–1148.
105. Wattmo C, Wallin AK, Londos E, Minthon L. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist 2011;51:17–27.
106. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 2004;21:607–620.
107. Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ 2014;15:791–800.
108. Alzheimer's Association. Available at http://www.alz.org/care/alzheimers-dementia-home-safety.asp#safetytips (accessed 21 November 2014).
109. Spangenberg KB, Wagner MT, Hendrix S, Bachman DL. Firearm presence in households of patients with Alzheimer's disease and related dementias. J Am Geriatr Soc 1999;47:1183–1186.
110. Greene E, Bornstein BH, Dietrich H. Granny, (don't) get your gun: competency issues in gun ownership by older adults. Behav Sci Law 2007;25:405–423.
111. Kunik ME, Snow AL, Davila JA, et al. Consequences of aggressive behavior in patients with dementia. J Neuropsychiatry Clin Neurosci 2010;22:40–47.
112. Kapp MB. Geriatric patients, firearms, and physicians. Ann Intern Med 2013;159:421–422.
113. Alzheimer's Association. Staying safe: steps to take for a person with dementia. Available at http://www.alz.org/national/documents/brochure_stayingsafe.pdf (accessed 21 November 2014).
114. Guerin O, Andrieu S, Schneider SM, et al. Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients. Am J Clin Nutr 2005;82:435–441.
115. Teaster P, Nerenberg L. A national look at elder abuse multidisciplinary teams. J Elder Abuse Negl 2003;15:91–107.
116. Buhr GT, Kuchibhatla M, Clipp EC. Caregivers' reasons for nursing home placement: clues for improving discussions with families prior to the transition. Gerontologist 2006;46:52–61.
117. Gaugler JE, Teaster P. The family caregiving career: implications for community-based long-term care practice and policy. J Aging Soc Policy 2006;18:141–154.
118. Haley WE. The family caregiver's role in Alzheimer's disease. Neurology 1997;48:S25–S29.
119. Mohamed S, Rosenheck R, Lyketsos CG, Schneider LS. Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates. Am J Geriatr Psychiatry 2010;18:917–927.
120. Alzheimer's Association. Food, eating and Alzheimer's. Available at http://www.alz.org/care/alzheimers-food-eating.asp (accessed 21 November 2014).
121. Alzheimer's Association. Dementia & driving resource center. Available at http://www.alz.org/care/alzheimers-dementia-and-driving.asp (accessed 21 November 2014).
122. Alzheimer's Association. Financial and legal planning. Available at http://www.alz.org/care/alzheimers-dementia-planning-ahead.asp (accessed 21 November 2014).
123. Alzheimer's Association. Abuse. Available at http://www.alz.org/care/alzheimers-dementia-elder-abuse.asp (accessed 21 November 2014).
124. Alzheimer's Association. Caregiver stress check. Available at http://www.alz.org/care/alzheimers-dementia-stress-check.asp (accessed 21 November 2014).
125. Alzheimer's Association. Caregiver support groups. Available at http://www.alz.org/care/alzheimers-dementia-support-groups.asp (accessed 21 November 2014).
126. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
127. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003;51:1451–1454.
128. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695–699.
129. Schmitt FA, Saxton JA, Xu Y, et al. A brief instrument to assess treatment response in the patient with advanced Alzheimer disease. Alzheimer Dis Assoc Disord 2009;23:377–383.
130. Galvin JE, Roe CM, Coats MA, Morris JC. Patient's rating of cognitive ability: using the AD8, a brief informant interview, as a self-rating tool to detect dementia. Arch Neurol 2007;64:725–730.
131. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997;11(suppl 2):S33–S39.
132. Kaufer DI, Cummings JL, Ketchel P, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000;12:233–239.